Neutra Corp.

NTRR

US64129C3034

Pharmaceuticals

Delayed OTC Markets Other stock markets 11:57:20 2024-04-29 am EDT			5-day change	1st Jan Change
0.00025 ^USD	+25.00%		0.00%	0.00%

2023	Neutra Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	CI
2023	Neutra Corp. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	CI

Neutra Corp. announced that it has received funding

January 31, 2019

Neutra Corp. (OTCPK:NTRR) announced a private placement of common shares on January 1, 2020.

Latest news about Neutra Corp.

Neutra Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	Dec. 15	CI
Neutra Corp. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	23-09-14	CI
Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2023	23-06-22	CI
Neutra Corp. Reports Earnings Results for the Full Year Ended January 31, 2023	23-06-09	CI
Neutra Corp. Auditor Raises 'Going Concern' Doubt	23-06-08	CI
Neutra Corp. executed a binding letter of intent to acquire Mercury Clinical Research, Inc.	23-01-29	CI
Neutra Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	22-12-15	CI
Neutra Corp. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	22-09-14	CI
Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2022	22-06-21	CI
Neutra Corp. Reports Earnings Results for the Full Year Ended January 31, 2022	22-05-10	CI
Neutra Corp. Auditor Raises 'Going Concern' Doubt	22-05-09	CI
Neutra Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021	21-12-10	CI
Neutra Corp. Reports Earnings Results for the Second Quarter Ended July 31, 2021	21-09-14	CI
Neutra Corp. acquired Deity Wellness.	21-06-22	CI
Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2021	21-06-21	CI
Neutra Corp. Reports Earnings Results for the Third Quarter Ended October 31, 2020	20-12-21	CI
Neutra Corp. Reports Earnings Results for the Second Quarter Ended July 31, 2020	20-09-14	CI
Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2020	20-07-14	CI
Neutra Corp.'s VIVIS Introduces three New Products into the CBD Marketplace	20-07-02	CI
Neutra Corp. announced that it has received funding	19-12-31	CI
Neutra Corp. Reports Earnings Results for the Third Quarter Ended October 31, 2019	19-12-23	CI
Neutra Corp. Reports Earnings Results for the Second Quarter Ended July 31, 2019	19-09-23	CI
Neutra Corp. completed the acquisition of Vivis Corporation from Sydney Jim and others.	19-09-09	CI
Neutra Corp. entered into letter of intent to acquire Vivis Corporation from Sydney Jim and others for $0.04 million.	19-07-25	CI
Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2019	19-06-14	CI

Neutra Corp. is an early-stage research and development company. The Company is engaged in marketing and participating in the nutraceutical space by bringing products derived from all natural and organic origins. The Company plans to research and bring new technology to the Nutraceutical space. The Company is primarily focused on participating in the medical cannabis market, which is a nutraceutical sub-market. It intends to entrust the manufacturing to a nutraceutical contractor to private label all of its products and to sell them under its brand. It primarily sells hemp-derived products, including products containing delta-8-THC and other cannabinoids. Its subsidiaries include Diamond Anvil Designs, LLC, Deity Corporation and Vivis Corporation.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NEUTRA CORP.	0.00%	584K
ELI LILLY AND COMPANY	+25.95%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.65%	352B
MERCK & CO., INC.	+19.35%	332B
ABBVIE INC.	+3.36%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.17%	145B